TickerFacts.

Aclarion, Inc. (ACON): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$7.19M
Year ended 2025-12-31
2023-12-31: -$3.65M2024-12-31: -$5.28M2025-12-31: -$7.19M-$7.19M
2023-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$7.19Mn/m2026-03-18, From 2025-01-01
2024-12-31-$5.28Mn/m2026-03-18, From 2024-01-01
2023-12-31-$3.65Mn/a2025-04-09, From 2023-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Aclarion, Inc. (ACON)2025-12-31-$7.19Mn/m
Sera Prognostics, Inc. (SERA)2025-12-31-$26.35Mn/m
YD Bio Ltd (YDES)2025-12-31-$8.04Mn/m
BioNexus Gene Lab Corp (BGLC)2025-12-31-$1.88Mn/m
American Shared Hospital Services (AMS)2025-12-31-$4.54Mn/m
Exagen Inc. (XGN)2025-12-31-$14.27Mn/m
Personalis, Inc. (PSNL)2025-12-31-$79.45Mn/m
Biodesix Inc (BDSX)2025-12-31-$23.53Mn/m
GRAIL, Inc. (GRAL)2025-12-31-$299.92Mn/m

Compare ACON, SERA, YDES, BGLC side by side · Screen every company in Services-Medical Laboratories ↗